AbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share. The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024. Elahere is considered a "first-in-class antibody-drug...
I was scanning stocks for chart patterns and came across Immunogen Inc. (IMGN) with a double-top already formed. IMGN has been trading in a downward channel since February 2021 and shows no sign of stopping yet. The price has reached a major support level of about 4.97, with only one major breach back in May. On three occasions it has dipped below slightly to...
The daily model for IMGN shows major move about to take place causing price to rise dramitically over next 12 months (if i am correct)